Glenmark Pharma will be reporting its Q3 earnings on Friday, February 12. The street is expecting revenue growth of around 3 percent, EBITDA is expected to come in with a growth of around 24 percent. The margins are expected at around 19 percent and profit growth of around 31 percent.

The key thing to watch out for is the recovery in the US market after the year-on-year (YoY) decline seen in Q2FY21 as sales start to normalise post the COVID-19. India growth is also expected to continue in terms of momentum because of the coronavirus portfolio. API sales are showing momentum as well.

CNBC-TV18’s Ekta Batra gets more details on what to expect from the numbers.

Watch the video for more

(Edited by : Ajay Vaishnav)